跳至主要内容
临床试验/RBR-7rk26hj
RBR-7rk26hj已完成Unknown

Evaluation of the treatment of Partial Rupture of the Supraspinatus Tendon with the Dry Needling technique associated with Platelet Rich Plasma

Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP0 个研究点开始时间: 2023年5月29日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方

研究概览

简要总结

The aim of this study was to compare the effects of barbotage of the supraspinatus tendon (ST) partial rupture with or without Platelet Rich Plasma (PRP) using the Western Ontario Rotator Cuff Index score, and ultrasound (US) images, at 6 weeks and 6 months after treatment. Patients showed clinical improvement in both groups, and no significant difference in the score at 6 weeks was found. However, at 6 months a significant improvement was observed in the PRP group (p=0,019). Supraspinatus Tendon rupture decreased in both groups after treatment, and there was a significant enhancement at 6 weeks and 6 months in the PRP group. In conclusion, US guided barbotage technique associated with PRP or saline solution are effective treatments for clinical improvement and decrease in the size of the partial ST tear, with better results with PRP in clinical improvement at 6 months. The association of PRP with barbotage is superior in reducing the size of the ST tear at 6 weeks and 6 months, reaching complete healing in 79,3% of the tears.

研究设计

研究类型
Interventional

入排标准

年龄范围
25Y 至 0(—)

入选标准

  • Patients of both sexes, aged over 25 years, with partial rupture of the supraspinatus less than or equal to 1 cm in the longitudinal axis evaluated by ultrasound.

排除标准

  • Patients who underwent any ultrasound-guided needling procedure in the affected tendon, use of infiltration with corticosteroids in the affected shoulder in the last 6 months, presence of another pathology of the shoulder to be treated (fracture or arthritis of rheumatic origin), cervical spine radiculopathy, pregnancy, neoplasm, severe liver disease or nephropathy, autoimmune, inflammatory or infectious diseases, acute or chronic, hypersensitivity to lidocaine, use of anti-inflammatory drugs or corticosteroids in any form before 6 weeks of application of platelet-rich plasma

研究者

发起方
Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP

相似试验